• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Baylor Scott & White Health and Contessa Announce Partnership to Create New Model of At-Home Care for Patients

    6/9/22 8:30:00 AM ET
    $AMED
    Medical/Nursing Services
    Health Care
    Get the next $AMED alert in real time by email

    DALLAS and NASHVILLE, Tenn., June 09, 2022 (GLOBE NEWSWIRE) -- Baylor Scott & White Health, the largest not-for-profit health system in Texas, and Contessa, an Amedisys company (NASDAQ:AMED) and the nation's leading high-acuity home care provider, announce a partnership to provide patients with a high-quality continuum of care in the home.

    The continuum of care will include new alternative care models to extend comprehensive, coordinated medical care to patients' homes, including hospital-level care, palliative or supportive care, and skilled nursing care. Baylor Scott & White will begin communicating the new programs to eligible patients in 2023.

    "We are dedicated to developing and delivering new, convenient options for our patients, offering high quality care when and where they want it," said Pete McCanna, chief executive officer at Baylor Scott & White. "These innovative at-home solutions will empower those we serve, enhancing the recovery process and improving outcomes."

    Once the programs are launched, eligible patients will be offered an alternative to conventional inpatient hospitalization as well as other services, including skilled nursing care at home and options for additional support and assistance for seriously ill patients, their families and caregivers. Data shows that Contessa's model reduces readmission rates by 44%, decreases the length of hospital stays by 35% and has a patient satisfaction rate of more than 90%.

    "We are thrilled to partner with Baylor Scott & White to offer greater options to patients, improving their experience," said Travis Messina, chief executive officer at Contessa. "Baylor Scott & White has a century-long reputation for providing high-quality care in the communities it serves, and we are eager to work collaboratively to soon provide hospital-level care to patients within the comfort and safety of their homes."

    About Baylor Scott & White Health:

    As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,100 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit BSWHealth.com

    About Contessa:

    Based in Nashville, Contessa is the leader and pioneer of Home Recovery Care, a risk-based model that combines all the essential elements of inpatient hospital care in the comfort of patients' homes. Founded in 2015, Contessa utilizes Care Convergence – a proprietary technology platform – to power the seamless delivery of Home Recovery Care that is safe, affordable and improves patient outcomes. Contessa's turnkey solution provides upfront savings to health plans, enables health systems to reinvent their care delivery model and helps physicians deliver a better experience for patients. For more information, visit contessahealth.com or follow us at @contessahealth.

    About Amedisys:

    Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility ("SNF") care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 549 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.

    Forward-Looking Statements:



    When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "will," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates, including potential staff shortages; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of patients and payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

    Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

     Contacts:
     Dana Schroering, Contessa

    (502) 727-0193

    [email protected]



    Julie Smith, Baylor Scott & White Health

    (940) 765-7560

    [email protected]



    Get the next $AMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMED

    DatePrice TargetRatingAnalyst
    7/29/2024$101.00Buy → Hold
    Deutsche Bank
    7/1/2024Outperform → Mkt Perform
    William Blair
    6/7/2023$97.00Buy → Hold
    Truist
    4/21/2023$87.00Neutral
    Cantor Fitzgerald
    3/13/2023$93.00Equal Weight
    Barclays
    10/27/2022Outperform → Mkt Perform
    Raymond James
    8/2/2022$145.00 → $95.00Neutral → Sell
    UBS
    6/29/2022$128.00Hold
    Stifel
    More analyst ratings

    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amedisys Reports First Quarter 2025 Financial Results

      BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 milli

      4/23/25 4:45:43 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

      BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, 2024 and 2023 Net service revenue increased $27.3 million to $598.1 million compared to $570.8 million in 2023.Net loss attributable to Amedisys, Inc. of $20.4 million, which is inclusive of merger-related expenses totaling $17.4 million ($15.9 million, net of tax) and a non-cash goodwill and other intangibles impairment charge totaling $48.4 million ($38.4 million, net of noncontrolling interest and tax) compared to net income attributable to Amedisys, Inc. of $19.3 milli

      2/26/25 4:30:12 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Honors 47 Employees With Annual Spirit of Excellence Award

      BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are privileged to have exceptional clinicians who consistently exceed expectations, and it is a profound honor to recognize their incredible commitment." Each year, the company honors Home

      2/3/25 6:30:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 171 shares, decreasing direct ownership by 2% to 7,943 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      6/3/25 8:18:53 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Guidroz Allyson sold $35,904 worth of shares (374 units at $96.00), decreasing direct ownership by 4% to 8,114 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/9/25 4:05:58 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 273 shares, decreasing direct ownership by 3% to 8,488 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/6/25 8:24:14 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amedisys downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00

      7/29/24 7:29:37 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by William Blair

      William Blair downgraded Amedisys from Outperform to Mkt Perform

      7/1/24 7:29:43 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by Truist with a new price target

      Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00

      6/7/23 9:03:46 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    SEC Filings

    See more
    • SEC Form 8-K filed by Amedisys Inc

      8-K - AMEDISYS INC (0000896262) (Filer)

      5/1/25 5:00:16 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form 10-K/A filed by Amedisys Inc

      10-K/A - AMEDISYS INC (0000896262) (Filer)

      4/29/25 4:12:39 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Amedisys Inc

      10-Q - AMEDISYS INC (0000896262) (Filer)

      4/24/25 8:02:23 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Amedisys Reports Second Quarter 2024 Financial Results

      BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa

      7/24/24 4:30:52 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports First Quarter 2024 Financial Results

      BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o

      4/24/24 4:45:46 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

      BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s

      2/21/24 4:30:11 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/13/24 4:58:48 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/12/24 5:24:28 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/8/24 10:18:47 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Financials

    Live finance-specific insights

    See more
    • AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

      BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

      5/3/23 4:31:00 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

      All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

      5/3/23 4:30:00 PM ET
      $AMED
      $OPCH
      Medical/Nursing Services
      Health Care
    • Amedisys Announces First Quarter 2023 Earnings Release and Conference Call Date

      BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

      4/20/23 8:00:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care